View Older Stories View More Recent Stories

Jan 13, 2020 04:02PM Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics
Jan 9, 2020 02:47PM Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th
Dec 23, 2019 08:30AM Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine
Dec 2, 2019 08:31AM Ligand Pharma (LGND) Enters into Worldwide OmniAb Platform License Agreement with Sanofi (SNY)
Dec 2, 2019 08:30AM Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi
Nov 12, 2019 08:30AM Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
Nov 8, 2019 08:30AM Ligand Pharma (LGND) Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Nov 8, 2019 08:30AM Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Nov 7, 2019 08:30AM Ligand to Participate in the Stephens 2019 Nashville Investment Conference
Nov 5, 2019 04:01PM Ligand Reports Third Quarter 2019 Financial Results
Oct 22, 2019 04:01PM Ligand to Report Third Quarter 2019 Results on November 5th
Oct 15, 2019 09:08AM Ligand Pharma (LGND) Announces Sarah Boyce to Board
Oct 15, 2019 09:00AM Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
Aug 29, 2019 09:00AM Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference
Aug 12, 2019 09:00AM Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
Jul 30, 2019 08:00AM Ligand Reports Second Quarter 2019 Financial Results
Jul 23, 2019 04:27PM Ligand Pharma (LGND) Acquires Ab Initio Biotherapeutics
Jul 23, 2019 04:15PM Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
Jul 16, 2019 11:19AM Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP
Jul 15, 2019 09:00AM Ligand to Report Second Quarter 2019 Results on July 30th
Jul 10, 2019 09:02AM Ligand Pharma (LGND) Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Jul 10, 2019 09:00AM Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Jul 8, 2019 08:32AM Ligand Pharma (LGND), SQ Innovation Enter into Exclusive Worldwide Captisol License and Supply Agreements for High-Concentration Furosemide Formulation
Jul 8, 2019 08:30AM Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
Jul 8, 2019 08:30AM Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
Jul 1, 2019 09:01AM Ligand Pharma (LGND) announces Sage Therapeutics has launched ZULRESSO
Jul 1, 2019 09:00AM ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics
Jun 12, 2019 09:05AM Ligand Pharma (LGND) Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration
Jun 12, 2019 09:00AM Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
May 17, 2019 09:03AM Ligand Pharma (LGND) Licenses VER250840 to Cumulus Oncology
May 17, 2019 09:00AM Ligand Licenses VER250840 to Cumulus Oncology
May 6, 2019 09:03AM Ligand Pharma (LGND) Acquires Milestone and Royalty Rights to SB206 from Novan (NOVN)
May 6, 2019 09:00AM Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
May 2, 2019 04:01PM Ligand Reports First Quarter 2019 Financial Results
May 2, 2019 09:09AM Ligand Pharma (LGND) Reports Complete Enrollment for Phase 1 Clinical Trial of Captisol-enabled Iohexol
May 2, 2019 09:00AM Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Apr 18, 2019 09:00AM Ligand to Report First Quarter 2019 Results on May 2nd
Mar 21, 2019 09:04AM Ligand Pharma (LGND) to receive $3 million milestone payment as result of FDA’s approval of Sage's ZULRESSOTM
Mar 21, 2019 09:00AM Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Mar 12, 2019 04:01PM Ligand to Participate in Four Upcoming Investor Conferences
Mar 12, 2019 10:00AM Ligand Provides Highlights from Today’s Analyst Day Event
Mar 5, 2019 04:07PM Ligand Pharma (LGND) Sells Promacta Assets and Royalty for $827 Million
Mar 5, 2019 04:01PM Ligand Sells Promacta Assets and Royalty for $827 Million
Feb 21, 2019 09:00AM Reminder: Ligand to Host Analyst Day on March 12th in New York City
Feb 7, 2019 04:01PM Ligand Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 7, 2019 09:00AM Ligand Announces OmniAb® Partnership with Genagon Therapeutics
Feb 4, 2019 04:12PM Ligand Pharma (LGND) Announces Investment in Dianomi Therapeutics
Feb 4, 2019 04:01PM Ligand Announces Investment in Dianomi Therapeutics
Jan 25, 2019 09:00AM Ligand Partner Seelos Therapeutics Becomes a Public Company
Jan 15, 2019 02:00PM Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th
View More Recent Stories View Older Stories